Genentech, a member of the Roche, today celebrated the grand opening of the Roche Genentech Innovation Center Boston. The center focuses on work in cardiovascular, renal and metabolic (CVRM) diseases.
Located at Harvard’s Enterprise Research Campus in Allston, the Roche Genentech Innovation Center Boston brings together scientists from across discovery research, clinical development, artificial intelligence and data science disciplines, and creates a research environment spanning early-stage discovery through late-stage clinical development.
The center complements established R&D teams in South San Francisco and Basel while connecting Roche and Genentech scientists more closely with researchers, talent and institutions across the Boston scientific and biotech ecosystem.
AI, machine learning and data science will be a part of the research center, with teams from Roche Product Development and Genentech Research and Early Development (gRED) working as part of an end-to-end R&D environment spanning discovery research through late-stage clinical development.
Roche and Genentech have signed a 10-year lease for the 95,000-square-foot center, which will have capacity for up to 500 people across research, clinical development, data science and other areas.
The Innovation Center is part of Roche and Genentech’s investment commitment in U.S. manufacturing and R&D and builds on recent investments and manufacturing milestones in Holly Springs, North Carolina, and Hillsboro, Oregon.
